Introduction
-Nineteen cases of IgE myeloma have been reported including the present one and five have been associated with plasma cell leukaemia (Johansson and Bennich, 1967; Ogawa et al., 1969; Sala et al., 1981; Endo et al., 1981) . Plasma cell leukaemia is itself found in only 1-6% of all cases of myeloma (Kyle, Maldonado and Bayrd, 1974) .
The number of cases now seems large enough to conclude that a definite association exists between IgE myeloma and plasma cell leukaemia. During these investigations, his haemoglobin dropped to 9-2 g/litre and his white cell count rose to 25 8 x 109/litre of which 61% were plasma cells. His blood urea rose to 33-0 mmol/litre.
He was rehydrated with intravenous fluids and his renal failure gradually improved. Therapy was commenced with melphalan 5 mg a day for 5 days, repeated at monthly intervals. The response was excellent with complete clearance of plasma cells from his peripheral blood in 7 days and resolution of his confusion.
However, after some months, he again became confused and was found to have a rising paraprotein level. Plasma cells reappeared in the peripheral blood. In spite of further chemotherapy, he died, 36 weeks after presentation.
Discussion
The features of IgE myeloma are becoming clearer. The age of onset (mean 62 years), sex ratio (53% male) and frequency of Bence Jones proteinuria (63%) are similar to ordinary myeloma (Kyle, 1975) . However, anaemia may be more frequent. The haemoglobin at presentation was less than 10 g/litre in 63% of IgE cases compared with 33% overall. In contrast, severe renal failure only occurred in three of the IgE cases although mild renal impairment is common (71% of IgE cases compared with 55% overall). The X-ray findings in IgE myeloma are cuious. Normal bone X-rays are more common (33% compared to 21%) and lytic bone lesions are less often seen (44% compared with 70%). Bone sclerosis is very rare in myeloma generally but has been found in two IgE cases (Rogers et al., 1977) . Because many case reports have been published before the patient's death, it is difficult to be precise about the prognosis; probably the survival is similar to myeloma generally, a median of about 20 months.
Although the numbers are small, it seems certain that the incidence of plasma cell leukaemia in IgE myeloma (26%) is genuinely much higher than in myeloma overall (1[6%). The factors controlling the release ofplasma cells into the blood are little known. It has been suggested that surface IgE increases the propensity for their release into the circulation but the mechanism is unknown.
